2. >>Business

Renalytix AI And AstraZeneca Collaborate To Improve Chronic Kidney Disease Outcomes

 
• By Marion Webb

The companies will launch "precision medicine strategies" for chronic disease that use Renalytix' AI-enabled IVDs.

Human Body Organs (Kidneys with Urinary Bladder)

Renalytix AI plc ’s KidneyIntelX artificial intelligence-enabled in vitro diagnostic platform will be bolstered by a new collaborative agreement with AstraZeneca PLC.

The companies announced on 21 August that they will team up to develop and launch precision strategies for heart, renal and metabolic diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield

 
• By Shubham Singh

Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By Marion Webb

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.